All Resources
Screening for T1D in Adults with Dysglycemia
Learn why dysglycemic adults are a priority population for T1D screening.
Think T1D in Adults Misclassified with T2D
Learn why T1D is often misclassified as T2D and how to differentiate the two in adults suspected of T1D .
The Future of Early T1D Detection: Integrating the Wider Care Team
Expert discussion of how diabetes teams can adapt to deliver monitoring, education, and psychosocial support for early-stage T1D care.
Early Detection Pathways in Primary Pediatric Care
Expert insights on how primary pediatric care pathways can help scale early T1D detection, from screening and staging to referral and monitoring.
The Evolving Landscape of Early Detection in T1D
Leading T1D experts discuss scaling up screening programs to support equitable access to early T1D detection, monitoring, and disease-modifying therapies.
Advancing Models of Care for People with Type 1 Diabetes
Leading T1D experts discuss supportive care pathways, psychosocial support, and new models of care for people at risk of, or diagnosed with, type 1 diabetes.
Communicating the Benefits of T1D Screening and Early Detection
Experts discuss how to effectively communicate the value of T1D screening and early detection to families, clinicians, and healthcare decision-makers.
Identifying Adult-onset T1D
Leading T1D experts explore how to distinguish adult-onset T1D from T2D and when to consider islet autoantibody testing in adults.
IDS 2026 Symposium Summary
In this panel Prof. Chantal Mathieu facilitated the discussion with Prof. Ezio Bonifacio, Prof. Thomas Kay, and Prof. John Wentworth. The speakers discussed biomarker-driven type 1 diabetes care, focusing on screening, diagnosis, and monitoring using autoantibodies, C-peptide, and glucose metrics. The panel highlighted the importance of early detection and risk stratification, reviewed immune-targeted therapies and emerging technologies, and emphasized key decision points supporting personalized, biomarker-guided T1D management.
This article is intended to be a summary only. Additional topics were covered in the live symposium in line with the applicable regulations but are not included on the BR1DGE platform.
Immune dysregulation in T1D: biomarkers and therapeutic targets
Profs. Kay and Bonifacio discuss the role of T-cell dysregulation as a central pathophysiological mechanism in T1D, and its implications for emerging therapies and biomarkers
Islet autoantibodies as biomarkers of progression to clinical T1D
Prof Bonifacio discusses the predictive value and utility of islet autoantibodies as biomarkers of the risk and rate of progression to clinical T1D
Composite risk scores as tools for improved T1D risk prediction
Prof. Wentworth discusses how T1D risk prediction can be improved through the development of tools that integrate multiple risk factors and biomarkers